DAXX
-
Official Full Name
death-domain associated protein -
Overview
Daxx is a ubiquitously expressed protein that was originally identified through a yeast two-hybrid screen as an interactor with the cytoplasmic domain of Fas. It was found to enhance Fas-mediated apoptosis and activate the JNK pathway (1). However, additi -
Synonyms
DAXX;death-domain associated protein;death associated protein 6;death domain-associated protein 6;DAP6;Fas-binding protein;CENP-C binding protein;ETS1-associated protein 1;death-associated protein 6;fas death domain-associated protein;EAP1;BING2;MGC126245;MGC126246
Recombinant Proteins
- Human
- Zebrafish
- Mouse
- E.coli
- Wheat Germ
- Mammalian Cells
- HEK293
- HeLa
- In Vitro Cell Free System
- GST
- His
- Non
- DDK
- Myc
- Avi
- Fc
- Flag
Involved Pathway
DAXX involved in several pathways and played different roles in them. We selected most pathways DAXX participated on our site, such as Amyotrophic lateral sclerosis (ALS),Androgen receptor signaling pathway,Apoptosis Modulation and Signaling, which may be useful for your reference. Also, other proteins which involved in the same pathway with DAXX were listed below. Creative BioMart supplied nearly all the proteins listed, you can search them on our site.
| Pathway Name | Pathway Related Protein |
|---|---|
| Integrated Pancreatic Cancer Pathway | TOP2A,FST,NOXA1,JUND,MST1,PPP1R13L,MAPK4,FKBP1B,RAPGEF3,IL11 |
| IL-6 Signaling Pathway | EIF2A,CDK5R1B,BMX |
| Apoptosis Modulation and Signaling | SEPT4,BAG3,BCL2L11,PTRH2,DIABLO,PTPN13,CAPNS1,BOK,CDKN2A,HRK |
| Herpes simplex infection | IFNAR2,CASP3B,TBPL1,HLA-DRA,PKZ,BF2,NFKB1,EEF1DB,IFNA8,HCFC2 |
| HIV-1 Nef: Negative effector of Fas and TNF-alpha | DFFA,CRADD,CASP2 |
| Amyotrophic lateral sclerosis (ALS) | GPX1,NEFH,TNFRSF1A,BAX,TP53,TNF,NOS1,MAP2K3,DERL1,MAPK11 |
| Androgen receptor signaling pathway | ETV5A,SVILA,HMGB2A,CMTM2A,PNRC1,KAT5,GNB2L1,KAT7,NR2C2,POU2F1B |
| FAS pathway and Stress induction of HSP regulation | DFFA,LMNB2,FAF1 |
Protein Function
DAXX has several biochemical functions, for example, androgen receptor binding,enzyme binding,heat shock protein binding. Some of the functions are cooperated with other proteins, some of the functions could acted by DAXX itself. We selected most functions DAXX had, and list some proteins which have the same functions with DAXX. You can find most of the proteins on our site.
| Function | Related Protein |
|---|---|
| protein homodimerization activity | TBC1D22A,THRA,IGJ,MAPK4,AADAT,TPR,CCDC88A,BOK,IKZF3,RIPK2 |
| protein kinase activator activity | STK11,CAB39,MARK2,DBF4B,NKX3-1,MAPK8IP2,PIK3CA,AGAP2,GPRC5B,NKX3 |
| enzyme binding | MSH3,DYM,RCOR2,SCARB2,HAND2,PARK2,CNTNAP2,CSF3,TOP2A,UBE4B |
| transcription factor binding | PAX6,TP53,SMAD2,ERCC3,NAAA,VDRA,DIP2BA,RELA,IFI16,CEBPA |
| protein kinase binding | CCNL1,PTPN23,SMAD1,TPRKB,TRIB3,LATS1,CCNT2B,CDH2,GATA4,CCNL1B |
| androgen receptor binding | RNF6,PRKCB,KDM4C,GRIP1,PRPF6,CTNNB1,KDM3A,DDX5,BRCA1,FOXP1 |
| ubiquitin protein ligase binding | VCP,SNX9,SCN5A,USP13,SMAD7,TRAF6,BAG6,RNF34,TRIB1,NPLOC4 |
| transcription corepressor activity | SKIL,DR1,PROX1,PAWR,CSDA,C1D,CDX2,HSBP1,NFKBIL2,AES |
| protein N-terminus binding | ID1,PHB2,NFE2,NPAT,NCOA3,EXOC4,ATM,CHMP6,STX1A,SUV39H1 |
Interacting Protein
DAXX has direct interactions with proteins and molecules. Those interactions were detected by several methods such as yeast two hybrid, co-IP, pull-down and so on. We selected proteins and molecules interacted with DAXX here. Most of them are supplied by our site. Hope this information will be useful for your research of DAXX.
MDM2;TP53
DAXX Related Signal Pathway
Resources
Gene Families
Research Area
Related Services
Related Products
References
- Schreiner, S; Kinkley, S; et al. SPOC1-Mediated Antiviral Host Cell Response Is Antagonized Early in Human Adenovirus Type 5 Infection. PLOS PATHOGENS 9:-(2013).
- Weisbrod, AB; Zhang, LS; et al. Altered PTEN, ATRX, CHGA, CHGB, and TP53 Expression Are Associated with Aggressive VHL-Associated Pancreatic Neuroendocrine Tumors. HORMONES & CANCER 4:165-175(2013).
